Generic Name and Formulations:
Cladribine 1mg/mL; soln for IV infusion after dilution; preservative-free.
Various generic manufacturers
Indications for Cladribine:
Active hairy cell leukemia.
Give by continuous IV infusion for 7 consecutive days. 0.09mg/kg per day.
See full labeling.
Delay or discontinue if neurotoxicity or renal toxicity occurs. Myelosuppression. Active infection. Renal or hepatic insufficiency. Monitor blood counts (esp. during first 4–8 weeks post-dose), renal and hepatic function. Pregnancy (Cat.D), nursing mothers: not recommended.
Live attenuated vaccines: not recommended. Increased toxicity with myelosuppressive, immunosuppressive, or nephrotoxic agents.
Chlorinated purine nucleoside analog.
Severe myelosuppression (eg, neutropenia, anemia, thrombocytopenia), fever, infection, fatigue, nausea, rash, headache, inj site reactions, others; neurotoxicity, nephrotoxicity, tumor lysis syndrome (rare).
Endocrinology Advisor Articles
- Triple-Goal Achievement Reduces Risk for Complications in Type 2 Diabetes
- Inverse Association Between Serum 25(OH)D Levels and Risk for Diabetes
- ADA Issues White Paper Addressing Escalating Cost of Insulin
- Neprilysin Inhibition May Reduce Renal Function Deterioration in Comorbid T2D and Chronic Heart Failure
- Serum Chemerin May Predict Risk for Spontaneous Abortion in Women With PCOS
- Diabetes Treatments
- Incretins, Thiazolidinediones Associated With Better Glycemic Control in T2D
- No Link Between HbA1c Levels and Wound Healing in Patients With Diabetic Foot Ulcers
- Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy
- Use of In-Hospital Continuous Subcutaneous Insulin Infusion: A Consensus Statement
- Effects of Gender on Clinical Outcomes in Empagliflozin-Treated Type 2 Diabetes
- Effect of Acetyl-L-Carnitine on Blood Pressure in Type 2 Diabetes
- PAH Risk, Mortality Increased by Disturbances in Male Sex Hormones
- Perioperative Cardiovascular Events More Common in Diabetes
- Individuals With Type 1 Diabetes See Improvement With Continuous Glucose Monitoring